Remember me
 |
Dendreon misses revs, rallies $6?Wed Aug 4th, 2010
David MillerDendreon (DNDN) missed revenue estimates but is rallying strongly toda |
|
Dendreon Provenge sales previewTue Aug 3rd, 2010
David MillerDendreon (DNDN) reports sales from the first two months of Provenge af |
|
Biotech randomsMon Aug 2nd, 2010
David MillerSome thoughts from biotech-land:
The 'Ville's Lisa LaMotta step |
 |
Dendreon's Provenge Costs the Same as ChemotherapyThu Jul 29th, 2010
David MillerThe price of the prostate cancer drug has been widely debated and is often wildly wrong. |
|
False Dendreon Rumors Spur Market ActionFri Jul 9th, 2010
David MillerInvestors thought a center that prescribes Provenge was backing out because of a Center for Medicaid Services announcement. |
|
Tempest in Dendreon's TeapotThu Jul 1st, 2010
David MillerInvestors in Dendreon (DNDN) got a nasty surprise after the close yest |
|
Aetna Confirms It Will Cover ProvengeTue Jun 22nd, 2010
David MillerOn June 15, six weeks after Provenge was approved, Aetna issued its opinion that Dendreon's drug was medically necessary and would be covered. |
|
Adolor misses againThu Jun 17th, 2010
David MillerAdolor (ADLR) misses again on trying to prove its delta targeted pain |
|
More info on Sanofi's JevtanaThu Jun 17th, 2010
David MillerSanofi Aventis (SNY) received approval for cabazitaxel (Jevtana) today |
|
Sanofi Aventis gets rapid approval of cabazitaxel for PCaThu Jun 17th, 2010
David MillerSanofi Aventis (SNY) was just granted rapid (11 weeks versus 24 weeks |
